Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring
Authors:
- Hélène PeyrièreHPHélène Peyrière
- 19 July 2010
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 40 (10) , 701-706
Abstract
Voriconazole (VRC), a triazole agent is extensively metabolized by CYP2C19, CYP2C9, and to a lesser extent, by CYP3A4. Few data are available regarding disposition of the main VRC metabolite (MVRC; UK121,265). The aim of this study was to investigate the pharmacokinetic variability of VRC and MVRC plasma concentrations on the basis of 115 drug monitoring samples from patients treated with VRC. Plasma concentrations of VRC and MVRC were determined by HPLC assay. During the study period, therapeutic drug monitoring (TDM) of 39 adult in- and out-patients were realized. The residual interquartile range (IQR) were 0.5–2.6 mg/l (median: 1.4 mg/l) for VRC plasma concentrations and 1.6–3.4 mg/l for MVRC (median: 2.5 mg/l). Median IQR metabolic ratio [VRC]/[MVRC] was 0.2–1.1 (median: 0.6 mg/l). VRC Cmin was Cmin Cmin ≥1 mg/l (median ratio 0.1 vs. 1.0 p < 0.0001). VRC TDM is now recommended to optimize their benefit/risk ratio. In addition, measurement of MVRC in unstable patients could quickly detect patients with impaired metabolism, in cases of subtherapeutic (Cmin 5 mg/l) VRC plasma levels.Keywords
This publication has 15 references indexed in Scilit:
- Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypesInternational Journal of Antimicrobial Agents, 2009
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered AgentsClinical Infectious Diseases, 2009
- Defining Targets for Investigating the Pharmacogenomics of Adverse Drug Reactions to Antifungal AgentsPharmacogenomics, 2008
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety OutcomesClinical Infectious Diseases, 2008
- Simultaneous Quantification of Voriconazole and Its N-Oxide Metabolite in Human Plasma by an Easy and Rapid Isocratic LC Method with UV DetectionChromatographia, 2008
- Random plasma concentrations of voriconazole decline over timeJournal of Infection, 2007
- Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic statusClinical Pharmacology & Therapeutics, 2004
- THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMANDrug Metabolism and Disposition, 2003
- Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation RegimensAntimicrobial Agents and Chemotherapy, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002